The present invention refers to protein kinase inhibitors and more specifically to inhibitors of the protein kinase c-Jun amino terminal kinase.
The present invention refers to protein kinase inhibitors and more specifically to inhibitors of the protein kinase c-Jun amino terminal kinase.
The solution contains peptide inhibitor(s) of protein kinase C βII (PKC βII) and/or of protein kinase C ζ (PKC ζ) and/or peptide activator(s) of protein kinase C δ (PKCδ).
Examples include antisense oligonucleotides that specifically bind human protein kinase C-alpha and human C-Raf protein kinase.
The present invention relates to protein kinase C (iota).
Compositions and methods are provided for modulating the expression of protein kinase C. Oligonucleotides are provided which are targeted to nucleic acids encoding PKC.
The methods involve administration of PKC inhibitors and derivatives.
The solution contains peptide inhibitor(s) of protein kinase C ÿ (PKC ÿ).
One of the key proteins is protein kinase C [PKC].
The method includes administering an inhibitor of delta protein kinase C (PKC) to the subject.
Methods of using these compounds for modulation of Protein kinase C-theta expression and for treatment of diseases associated with expression of Protein kinase C-theta are provided.
The present invention is also directed to compounds that stabilize the open conformation of a protein kinase, a crystallized protein kinase ih the open conformation, and uses thereof.
Cardioprotection by epsilon-protein kinase c activation from ischemia: continuous delivery and antiarrhythmic effect of an epsilon-protein kinase c-activating peptide.
These may originate with protein kinase C, cAMP/ protein kinase A, and calcium release.
The present invention relates to the treatment and prevention of conditions wherein protein Kinase C inhibition is indicated.
These may originate with protein kinase C, cAMP/ protein kinase A, and calcium release.
The composition contains a peptide inhibitor of protein kinase C βΙΙ and/or Go 6983.
This suppresses the protein kinase C’s activation.
activation of protein kinase C and release of Ca²⁺
The invention concerns the identification of protein kinase inhibitors that preferentially bind to the inactive conformation of a target protein kinase.
The polypeptides according to the invention bind Protein Kinase C when this is in an activated form.
The compositions comprise oligonucleotides, targeted to nucleic acid encoding protein kinase C-iota.
The present invention relates to compounds of formula I useful in the inhibition of c-Met protein kinase.
The present invention relates to compounds of formula (I) useful in the inhibition of c- Met protein kinase.
The present invention relates to compound (1), which is useful in the inhibition of c-Met protein kinase.
Requêtes fréquentes français :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Requêtes fréquentes anglais :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Traduction Translation Traducción Übersetzung Tradução Traduzione Traducere Vertaling Tłumaczenie Mετάφραση Oversættelse Översättning Käännös Aistriúchán Traduzzjoni Prevajanje Vertimas Tõlge Preklad Fordítás Tulkojumi Превод Překlad Prijevod 翻訳 번역 翻译 Перевод